KWKerri Wachter
Kerri Wachter
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kerri Wachter has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Cardinale B. Smith
Icahn School of Medicine at Mount Sinai, New York, NY
1 shared publication - Daniel A. Mulrooney
Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, USA
1 shared publication - Daniel J. George
Duke Cancer Institute Durham North Carolina USA
1 shared publication - Douglas E. Peterson
School of Dental Medicine, UConn Health, Farmington, CT
1 shared publication Helen MacKay
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
1 shared publicationHoward A. Burris
Sarah Cannon Research Institute, Nashville, TN
1 shared publication
Latest Publications
- 1 April 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (10) , 1165-1184
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
- 1 April 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (10) , 1165-1184
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
- 1 December 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (12) , 548-549
Bevacizumab improves survival in HER2-positive metastatic disease
- 1 December 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (12) , 548-549
Bevacizumab improves survival in HER2-positive metastatic disease
- 1 October 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (10) , 461
Pemetrexed/bevacizumab maintenance combination stalls lung cancer
- 1 October 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (10) , 461
Pemetrexed/bevacizumab maintenance combination stalls lung cancer
- 1 October 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (10) , 461-462
Iniparib adds no survival benefit in lung cancer trial
- 1 October 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (10) , 461-462
Iniparib adds no survival benefit in lung cancer trial
- 1 October 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (10) , 459-460
Trastuzumab-based T-DM1 delays breast cancer progression
- 1 October 2011
- Published by Elsevier in Community Oncology
- Vol. 8 (10) , 459-460
Trastuzumab-based T-DM1 delays breast cancer progression
- 1 March 2006
- Published by Elsevier in Internal Medicine News
- Vol. 39 (5) , 49
Community-Acquired Variety Tops MRSA Worries
- 1 March 2006
- Published by Elsevier in Internal Medicine News
- Vol. 39 (5) , 49
Community-Acquired Variety Tops MRSA Worries